HER2-positive breast cancer: is more treatment better?
Mené sur 2 840 patientes atteintes d'un cancer du sein HER2+ de stade précoce, cet essai international randomisé de phase III évalue l'efficacité, du point de vue de la survie sans maladie invasive, et la toxicité du nératinib pendant 12 mois après un traitement adjuvant à base de trastuzumab (durée médiane de suivi : 24 mois)
Trastuzumab is a HER2-targeted monoclonal antibody that improves disease-free and overall survival when added to chemotherapy for treatment of early stage HER2-positive breast cancer. Follow-up data from the NSABP B-31 and NCCTG 9831 trials and the BCIRG 006 trial show overall survival rates of 83–86% at 8–10 years—a victory for a disease subtype previously associated with poor prognosis. Despite these findings, up to a quarter of patients will have disease recurrence. Various approaches have been tested to further improve outcome.